CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 58 enrolled
Drug / intervention
Plerixafor +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00903968
NCT00903968Phase 2Completed
CompareCT.gov

Phase I/II Trial of Combination Plerixafor (AMD3100) and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

Dana-Farber Cancer Institute·interventional·Posted May 19, 2009·Updated Jun 2, 2020

In Brief

A Phase 2 clinical trial evaluating Plerixafor, bortezomib, and 1 other intervention for Multiple Myeloma. Completed, enrolled 58 participants across 5 sites.

Detailed Summary

The purpose of this research study is to determine the safety of plerixafor and bortezomib, and the highest dose that can be given to people safely. Plerixafor appears to stop myeloma cells from attaching to bone marrow and has been used in other phase I studies for mobilization of stem cells for patients with myeloma and lymphoma. We have shown that the combination of plerixafor and bortezomib is very effective in killing myeloma cells in the laboratory more than the effect of each drug alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Genzyme, a Sanofi Company, Millennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 19, 2009
Enrollment StartJun 1, 2009
Primary CompletionJun 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 17.1 years ago

Interventions

Plerixafordrug

bortezomibdrug

Dexamethasonedrug